Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA® (pembrolizumab) for patients with cancer
2023-03-22 12:36:00
BEIJING, SHANGHAI and BOSTON, March 22, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has entered into a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate the combination of Jacobio's CD73 monoclonal antibody JAB-BX102 in combination with Merck & Co., Inc., Rahway, NJ, USA's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).
The clinical study will evaluate the clinical effect of JAB-BX102 in combination with KEYTRUDA for the treatment of advanced solid tumors. Under the terms of the agreement, Merck & Co., Inc., Rahway, NJ, USA will provide KEYTRUDA®.
"The CD73 monoclonal antibody is Jacobio's first large molecule project to enter the clinic. CD73 is an important target in the tumor immune pathway. We believe the combination of CD73 and anti-PD-1, an inhibitor on the same tumor immune pathway, can potentially relieve immunosuppression in the tumor microenvironment, stimulate the proliferation and activation of killer immune cells, enhance tumor immunity," said Dr. WANG Yinxiang, Chairman and CEO at Jacobio. "We look forward to exploring the potential benefit of CD73 in combination with an anti-PD-1 in tumor immunotherapy through this collaboration with Merck & Co., Inc., Rahway, NJ, USA and potentially giving patients new treatment options."
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
About JAB-BX102
JAB-BX102 is a humanized CD73 monoclonal antibody developed by Jacobio that was granted approvals for clinical trials in the U.S. and China in October 2021 and March 2022. Jacobio is currently initiating a Phase I/IIa, multi-center, open study of the safety, tolerability, pharmacokinetics and preliminary anti-tumor efficacy of JAB-BX102 alone and in combination with pablizumab to treat advanced solid tumors in China and the U.S. Current published clinical data show that CD73 in combination with PD-(L)1 significantly prolongs survival of patients with non-small cell lung cancer.
About Jacobio
Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions to improve people's health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform. Please visit us at www.jacobiopharma.com.
Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to the Company, are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment, and political, economic, legal and social conditions in China.
The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
PR Newswire News
- 15:23:00
- Nexteer Chongqing Celebrates 10th Anniversary & Production Milestone of 5 Million Electric Power Steering Systems
- 12:29:00
- /C O R R E C T I O N -- Roborock/
- 10:42:00
- Alphamab Oncology Reports Full Year 2023 Financial Results and Business Highlights
- 10:00:00
- Trip.com Group secures coveted spot on Fortune Asia Future 30 list, among Asia's most innovative and high-growth companies
- 08:50:00
- Jacobio Pharma Announces 2023 Annual Results
- 08:00:00
- Fosun Management on 2023 Annual Results: Focusing on Core Industries with Established Advantages
- 23:40:00
- Shenwan Hongyuan Announces 2023 Annual Results
- 22:46:00
- Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future
- 22:32:00
- Broncus Medical (02216.HK) Announces Annual Results for 2023
- 22:13:00
- Full Schedule Released for Hong Kong Web3 Festival 2024
- 22:10:00
- Harbour BioMed Reports Full Year 2023 Financial Results
- 22:07:00
- TCL Electronics (01070.HK) Profitability Significantly Improves in 2023
- 20:29:00
- Baguio Green's 2023 Adjusted Net Profit increased by 36.7%
- 18:40:00
- iClick Appoints Ms. Josephine Ngai as Chief Financial Officer
- 18:31:00
- Tigermed Reports Full Year 2023 Results
- 18:19:00
- HKbitEX Receives Approval-In-Principle For Virtual Asset Trading Platform (SFC Type 1 & 7) Licences
- 17:55:00
- AAC Technologies' Revenue in 2024 is Expected to Increase by 10-15%, PSS Automotive Business Revenue will Exceed RMB3 Billion
- 17:43:00
- Keep Inc. Announces 2023 Annual Results
- 17:09:00
- Sirnaomics Announces 2023 Annual Results
- 16:53:00
- Guo Guangchang: "Focus on building sustainable, predictable and enterprise with stable profit growth "